These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

124 related items for PubMed ID: 25641239

  • 1. Progression of renal damage in glycogen storage disease type I is associated to hyperlipidemia: a multicenter prospective Italian study.
    Melis D, Cozzolino M, Minopoli G, Balivo F, Parini R, Rigoldi M, Paci S, Dionisi-Vici C, Burlina A, Andria G, Parenti G.
    J Pediatr; 2015 Apr; 166(4):1079-82. PubMed ID: 25641239
    [Abstract] [Full Text] [Related]

  • 2. Efficacy of ACE-inhibitor therapy on renal disease in glycogen storage disease type 1: a multicentre retrospective study.
    Melis D, Parenti G, Gatti R, Casa RD, Parini R, Riva E, Burlina AB, Dionisi Vici C, Di Rocco M, Furlan F, Torcoletti M, Papadia F, Donati A, Benigno V, Andria G.
    Clin Endocrinol (Oxf); 2005 Jul; 63(1):19-25. PubMed ID: 15963056
    [Abstract] [Full Text] [Related]

  • 3. [Renal involvement in glycogen storage disease type 1: Practical issues].
    Ben Chehida A, Bensmaïl T, Ben Rehouma F, Ben Abdelaziz R, Azzouz H, Boudabbous H, Slim Abdelmoula M, Abdelhak S, Kaabachi N, Ben Turkia H, Tebib N.
    Nephrol Ther; 2015 Jul; 11(4):240-5. PubMed ID: 25957470
    [Abstract] [Full Text] [Related]

  • 4. Lipid status and linear relationship between total cholesterol and triglycerides in glycogen storage disease type I.
    Zhang ZJ, Yuan YH, Ma MS, Hong YH, Sun ZX, Xu YW, Wei M, Qiu ZQ.
    Eur Rev Med Pharmacol Sci; 2020 Oct; 24(19):10036-10044. PubMed ID: 33090409
    [Abstract] [Full Text] [Related]

  • 5. Intensive versus conventional therapy to slow the progression of idiopathic glomerular diseases.
    Bianchi S, Bigazzi R, Campese VM.
    Am J Kidney Dis; 2010 Apr; 55(4):671-81. PubMed ID: 20097461
    [Abstract] [Full Text] [Related]

  • 6. Renal function in glycogen storage disease type I, natural course, and renopreservative effects of ACE inhibition.
    Martens DH, Rake JP, Navis G, Fidler V, van Dael CM, Smit GP.
    Clin J Am Soc Nephrol; 2009 Nov; 4(11):1741-6. PubMed ID: 19808227
    [Abstract] [Full Text] [Related]

  • 7. Effect of lipid reduction on the progression of renal disease: a meta-analysis.
    Fried LF, Orchard TJ, Kasiske BL.
    Kidney Int; 2001 Jan; 59(1):260-9. PubMed ID: 11135079
    [Abstract] [Full Text] [Related]

  • 8. Short-term effect of captopril on microalbuminuria in children with glycogen storage disease type Ia.
    Ozen H, Ciliv G, Koçak N, Saltik IN, Yüce A, Gürakan F.
    J Inherit Metab Dis; 2000 Jul; 23(5):459-63. PubMed ID: 10947200
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia).
    Lancet; 1997 Jun 28; 349(9069):1857-63. PubMed ID: 9217756
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Hyperfiltration and renal disease in glycogen storage disease, type I.
    Baker L, Dahlem S, Goldfarb S, Kern EF, Stanley CA, Egler J, Olshan JS, Heyman S.
    Kidney Int; 1989 Jun 28; 35(6):1345-50. PubMed ID: 2671467
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Renal disease in an adult with type 1 glycogen storage disease.
    Kiyama S, Kitamoto Y, Nakayama M, Fukui H, Arima S, Tomita M, Inoue T, Sato T.
    Nihon Jinzo Gakkai Shi; 1991 Jan 28; 33(1):81-5. PubMed ID: 2038136
    [Abstract] [Full Text] [Related]

  • 15. Effectively "cross-bridged" hemostatic and blood screening test defects due to glycogenosis type 1 associated extremely hyperlipidemia.
    Balint B, Todorovic-Balint M, Petakov M, Ostojic G, Vucetic D.
    Transfus Apher Sci; 2014 Apr 28; 50(2):314-5. PubMed ID: 24556126
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Evolution of glomerular filtration rate, renal injury markers, anemia, and angiotensin blockers use after change from calcineurin inhibitors to sirolimus in transplant patients with neoplasia versus chronic allograft nephropathy.
    Luna E, Cerezo I, Macias R, Villa J, Martinez C, Cubero J, Martinez R, Ferreira F, García C.
    Transplant Proc; 2011 Apr 28; 43(6):2187-90. PubMed ID: 21839229
    [Abstract] [Full Text] [Related]

  • 18. Proteinuria and microalbuminuria in adults: significance, evaluation, and treatment.
    Venkat KK.
    South Med J; 2004 Oct 28; 97(10):969-79. PubMed ID: 15558924
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Increased lipogenesis and resistance of lipoproteins to oxidative modification in two patients with glycogen storage disease type 1a.
    Bandsma RH, Rake JP, Visser G, Neese RA, Hellerstein MK, van Duyvenvoorde W, Princen HM, Stellaard F, Smit GP, Kuipers F.
    J Pediatr; 2002 Feb 28; 140(2):256-60. PubMed ID: 11865283
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.